MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 530400 | Name: YK11
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

YK-11 is a synthetic, steroidal selective androgen receptor modulator (SARM). It is a gene-selective partial agonist of the androgen receptor (AR) and does not induce the physical interaction between the NTD/AF1 and LBD/AF2 (known as the N/C interaction), which is required for full transactivation of the AR. The drug has anabolic activity in vitro in C2C12 myoblasts and shows greater potency than dihydrotestosterone (DHT) in this regard.

Chemical Structure

YK11
YK11
CAS#1370003-76-1

Theoretical Analysis

MedKoo Cat#: 530400

Name: YK11

CAS#: 1370003-76-1

Chemical Formula: C25H34O6

Exact Mass: 430.2355

Molecular Weight: 430.54

Elemental Analysis: C, 69.74; H, 7.96; O, 22.30

Price and Availability

Size Price Availability Quantity
25mg USD 90.00 Ready to ship
50mg USD 135.00 Ready to ship
100mg USD 200.00 Ready to ship
500mg USD 550.00 Ready to ship
1g USD 950.00 Ready to ship
2g USD 1,650.00 Ready to ship
5g USD 3,650.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
YK-11; YK 11; YK11.
IUPAC/Chemical Name
methyl (E)-2-((8R,9S,10R,13S,14S,17R)-2'-methoxy-2',13-dimethyl-3-oxo-1,2,3,6,7,8,9,10,11,12,13,14,15,16-tetradecahydrospiro[cyclopenta[a]phenanthrene-17,4'-[1,3]dioxolan]-5'-ylidene)acetate
InChi Key
KCQHQCDHFVGNMK-DEIKBOPOSA-N
InChi Code
InChI=1S/C25H34O6/c1-23-11-9-18-17-8-6-16(26)13-15(17)5-7-19(18)20(23)10-12-25(23)21(14-22(27)28-3)30-24(2,29-4)31-25/h13-14,17-20H,5-12H2,1-4H3/b21-14+/t17-,18+,19+,20-,23-,24?,25-/m0/s1
SMILES Code
C[C@@]12[C@](/C3=C\C(OC)=O)(OC(OC)(O3)C)CC[C@@]1([H])[C@]4([H])CCC5=CC(CC[C@]5([H])[C@@]4([H])CC2)=O
Appearance
White to off-white solid powder.
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
YK11 is a partial agonist of androgen receptor with osteogenic activity.
In vitro activity:
A novel steroid compound, (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11), was found to be a partial agonist of the androgen receptor (AR) in an androgen responsive element (ARE)luciferase reporter assay. YK11 accelerates nuclear translocation of AR. Furthermore, YK11 does not induce amino/carboxyl-terminal (N/C) interaction and prevents 5-α-dihydrotestosterone (DHT)-mediated N/C interaction. Thus, YK11 activates AR without causing N/C interaction, which may in turn be responsible for the partially agonistic nature of YK11 observed in the ARE-luciferase reporter system. YK11 acts as a gene-selective agonist of AR in MDA-MB 453 cells. The effect of YK11 on gene expression relative to that of androgen agonist varies depending on the gene context. YK11 activated the reporter gene by inducing the translocation of the AR into the nuclear compartment, where its amino-terminal domain (NTD) functions as a constitutive activator of AR target genes. These results suggest that YK11 might act as selective androgen receptor modulator (SARM). Reference: Biol Pharm Bull. 2011;34(3):318-23. https://pubmed.ncbi.nlm.nih.gov/21372378/
In vivo activity:
The effect of YK11 on the pathophysiology of sepsis was tested. Sepsis was induced by i.p. injection of E. coli K1 at 1 × 108 CFU/mouse into mice that had a daily uptake of YK11 (6 h/3 times/day). YK11 injection at 350 and 700 mg/kg increased the survival rate of septic mice by 20% and 40%, respectively, within 72 h (Fig. 2A). YK11 also significantly reduced endotoxin levels in the serum (Fig. 2B), and the levels of inflammatory cytokines TNF-α, IL-1β, IL-6, IL-12p70, and IL-10 in the lungs of mice (Fig. 2C). Additionally, the levels of organ damage biomarkers—aspartate aminotransferase (AST), alanine aminotransferase (ALT) in the liver and blood urea nitrogen (BUN) in the kidneys—were alleviated by YK11 (Fig. 2D). Furthermore, YK11 promoted bacterial clearance from the organs of septic mice (Fig. 2E). It is YK11 effect was also shown against CRAB (Fig. S2). These data suggest that YK11 prevent septic mice caused by gram-negative bacteria by regulating inflammatory cytokine levels. Reference: Biochem Biophys Res Commun. 2021 Mar 5;543:1-7. https://pubmed.ncbi.nlm.nih.gov/33588136/
Solvent mg/mL mM
Solubility
DMSO 64.0 148.65
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 430.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Lee SJ, Gharbi A, Shin JE, Jung ID, Park YM. Myostatin inhibitor YK11 as a preventative health supplement for bacterial sepsis. Biochem Biophys Res Commun. 2021 Mar 5;543:1-7. doi: 10.1016/j.bbrc.2021.01.030. Epub 2021 Feb 12. PMID: 33588136. 2. Piper T, Dib J, Putz M, Fusshöller G, Pop V, Lagojda A, Kuehne D, Geyer H, Schänzer W, Thevis M. Studies on the in vivo metabolism of the SARM YK11: Identification and characterization of metabolites potentially useful for doping controls. Drug Test Anal. 2018 Nov;10(11-12):1646-1656. doi: 10.1002/dta.2527. Epub 2018 Nov 18. PMID: 30379415. 3. Yatsu T, Kusakabe T, Kato K, Inouye Y, Nemoto K, Kanno Y. Selective Androgen Receptor Modulator, YK11, Up-Regulates Osteoblastic Proliferation and Differentiation in MC3T3-E1 Cells. Biol Pharm Bull. 2018;41(3):394-398. doi: 10.1248/bpb.b1700748. PMID: 29491216. 4. Kanno Y, Hikosaka R, Zhang SY, Inoue Y, Nakahama T, Kato K, Yamaguchi A, Tominaga N, Kohra S, Arizono K, Inouye Y. (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor. Biol Pharm Bull. 2011;34(3):318-23. doi: 10.1248/bpb.34.318. PMID: 21372378.
In vitro protocol:
1. Yatsu T, Kusakabe T, Kato K, Inouye Y, Nemoto K, Kanno Y. Selective Androgen Receptor Modulator, YK11, Up-Regulates Osteoblastic Proliferation and Differentiation in MC3T3-E1 Cells. Biol Pharm Bull. 2018;41(3):394-398. doi: 10.1248/bpb.b1700748. PMID: 29491216. 2. Kanno Y, Hikosaka R, Zhang SY, Inoue Y, Nakahama T, Kato K, Yamaguchi A, Tominaga N, Kohra S, Arizono K, Inouye Y. (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor. Biol Pharm Bull. 2011;34(3):318-23. doi: 10.1248/bpb.34.318. PMID: 21372378.
In vivo protocol:
1. Lee SJ, Gharbi A, Shin JE, Jung ID, Park YM. Myostatin inhibitor YK11 as a preventative health supplement for bacterial sepsis. Biochem Biophys Res Commun. 2021 Mar 5;543:1-7. doi: 10.1016/j.bbrc.2021.01.030. Epub 2021 Feb 12. PMID: 33588136. 2. Piper T, Dib J, Putz M, Fusshöller G, Pop V, Lagojda A, Kuehne D, Geyer H, Schänzer W, Thevis M. Studies on the in vivo metabolism of the SARM YK11: Identification and characterization of metabolites potentially useful for doping controls. Drug Test Anal. 2018 Nov;10(11-12):1646-1656. doi: 10.1002/dta.2527. Epub 2018 Nov 18. PMID: 30379415.
1: Kanno Y, Ota R, Someya K, Kusakabe T, Kato K, Inouye Y. Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression. Biol Pharm Bull. 2013;36(9):1460-5. PubMed PMID: 23995658. 2: Kanno Y, Hikosaka R, Zhang SY, Inoue Y, Nakahama T, Kato K, Yamaguchi A, Tominaga N, Kohra S, Arizono K, Inouye Y. (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21- carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor. Biol Pharm Bull. 2011;34(3):318-23. PubMed PMID: 21372378.